References by our Clients to Oncolines®, SynergyFinder™, Mechanistic Cell Biology:
- King et al. (2022) Screening of NXP900 and dasatinib across 121 cancer cell lines identifies differences in their antiproliferative activity profiles. Poster presentation at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. (Affiliation: University of Edinburgh, Cancer Research U.K., and Nuvectis Pharma Inc.)
- Hughes et al. (2022) Uncovering the molecular mechanisms which predict sensitivity to a novel SRC kinase inhibitor NXP900 to inform personalized healthcare strategies. Poster presentation at AACR Annual Meeting 2022. (Affiliation: Cancer Research U.K., University of Edinburgh, and Nuvectis Pharma Inc.)
- Lane et al. (2022) BAL0891: a novel dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division resulting in potent anti-cancer activity. Poster presentation at AACR Annual Meeting 2022. (Affiliation: Basilea Pharmaceutica International Ltd.)
- Lane et al. (2022) BAL0891: a novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) with potent single agent activity. Poster presentation at ESMO TAT conference 2022. (Affiliation: Basilea Pharmaceutica International Ltd.)
- Cordo et al. (2022) Phosophoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies. Nature Communications, 13:1048. (Affiliation: Prinses Máxima Center for Pediatric Oncology)
- van der Zwet et al. (2021) MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance. Leukemia, 35 (12):3394-3405. (Affiliation: Prinses Máxima Center for Pediatric Oncology)
- Beauchamp et al. (2020) Targeting N-myristoylation for therapy of B-cell lymphomas. Nature Communications, 11:5348. (Affiliations: University of Alberta and Pacylex Pharmaceuticals)
- Borsari et al. (2019) Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl−Pyrimidine Moiety. ACS Medicinal Chemistry Letters, 10:1473-1479. (Affilitations: University of Basel and PIQUR Therapeutics AG)
- Rageot et al. (2019) (S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase. Journal of Medicinal Chemistry, 62 (13):6241-6261. (Affiliations: University of Basel and PIQUR Therapeutics AG)
- Grünewald et al. (2019) Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models. International Journal of Cancer, 145 (5): 346-1357. (Affiliation: Bayer AG)
- Gentile et al. (2018) A Novel Interaction Between the TLR7 and a Colchicine Derivative Revealed Through a Computational and Experimental Study. Pharmaceuticals, 11 (1):22. (Affiliation: University of Alberta)
- Bohnacker et al. (2017) Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. Nature Communications, 8:14683. (Affiliation: University of Basel)
- Politz et al. (2017) Preclinical activity of the FGFR inhibitor rogaratinib (BAY 1163877) alone or in combination with antihormonal therapy in breast cancer. Cancer Research, 77 (13 Supplement):1079. (Affiliation: Bayer AG)
- Li et al. (2016) IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study. PLoS Med, 13 (12):e1002200. (Affiliations: Erasmus MC and NTRC)
- Canté-Barrett et al. (2016) MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia. Leukemia, 30:1832-1843. (Affiliations: Erasmus MC and NTRC)
- Maia et al. (2015) Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model. Annals of Oncology, 26 (10):2180-2192. (Affiliations: Netherlands Cancer Institute and NTRC)
- Cmiljanovic et al. (2015) PQR309: Structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor, Cancer Research, 75 (15 Supplement):2664-2664. (Affiliation: PIQUR Therapeutics AG)
- Hudlebusch et al. (2014) The development of therapeutic inhibitors of the KDM5 histone demethylases, Cancer Research, 74 (19 Supplement): 5161-5161. (Affiliation: EpiTherapeutics)